rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Ernexa Therapeutics Inc.

ERNA · Nasdaq

Health CareBiotechnologyNot moving yet

ERNA stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 61.7% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
18% -9 in 4 wk
Insider buys, 12 months
$4.0M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
9 (-10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

23 Apr – 22 Oct
18%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Charles Cherington10% ownerbought4,000,000at $0.5010 Feb 2026filed 17 Feb 2026
Charles Cherington10% ownerbought4,000,00010 Feb 2026filed 17 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders9-10 on the quarter
New · exited1 · 10
Reported value$236K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCreduced · filed 14 Aug 202615,104$100K-17,972−54.3%
VANGUARD FIDUCIARY TRUST COreduced · filed 13 Aug 20268,336$55K-17,111−67.2%
Dauntless Investment Group, LLCreduced · filed 13 Aug 20266,000$40K-606,443−99.0%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20265,684$38K-20,820−78.6%
Tradewinds Capital Management, LLCnew · filed 24 Jul 2026361$2,401+361
BlackRock, Inc.reduced · filed 7 Aug 202633$219-787−96.0%
ASSETMARK, INCreduced · filed 30 Jul 20265$33-128−96.2%
BNP PARIBAS FINANCIAL MARKETSreduced · filed 13 Aug 20261$7-9−90.0%
SBI Securities Co., Ltd.reduced · filed 23 Jul 20261$7-5−83.3%
30 Jun 2025 – 30 Jun 2026
91419Jun 25Sep 25Dec 25Mar 26Jun 26

News

Everyone who traded it

David Polinsky Company insiderDirector · last 31 Aug 20260 · 0
Elena Ratner Company insiderDirector · last 31 Aug 20260 · 0
James Arthur Bristol Company insiderDirector · last 31 Aug 20260 · 0
Peter Cicala Company insiderDirector · last 31 Aug 20260 · 0
Sanjeev Luther Company insiderPresident and CEO · last 31 Aug 20260 · 0
William A. Wexler Company insiderDirector · last 31 Aug 20260 · 0
Charles Cherington Company insider10% owner · last 10 Feb 20266 · 2
Sandra M. Gurrola Company insiderSr. VP of Finance · last 21 Jun 20250 · 0
Dorothy J. Clarke Company insiderGeneral Counsel · last 1 Jan 20240 · 0
Freebird Partners Lp Company insider10% owner · last 15 Dec 20230 · 0
Curtis W. Huff Company insider10% owner · last 14 Jul 20230 · 0
Brant Binder Company insiderDirector · last 13 Jul 20230 · 0

Same industry

MRNA ModernaLeading+118%
ENTX Entera BioLeading+51%
XNCR XencorLeading+44%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 12 Mar 2026271%
Cash and equivalentsFY 2025 · to 31 Dec 2025$1.9M
Free cash flowFY 2025 · to 31 Dec 2025−$7.1M

Analyst forecasts

No analyst forecasts yet.